Welcome to our dedicated page for Generation Bio news (Ticker: GBIO), a resource for investors and traders seeking the latest updates and insights on Generation Bio stock.
Generation Bio Co. has reported biotechnology and corporate-status developments tied to its historical focus on genetic-medicine approaches for T cell-driven autoimmune diseases. Company updates have covered the ctLNP cell-targeted lipid nanoparticle delivery system, siRNA delivery to T cells, operating and financial results, stock and listing-related actions, equity awards, and leadership transitions.
Later public disclosures also place GBIO in a corporate transition context, with strategic-alternatives language followed by regulatory records addressing delisting and Exchange Act deregistration notices for its common stock.
Generation Bio Co. (Nasdaq: GBIO) reported significant progress in its non-viral gene therapy platform during the 24th ASGCT Annual Meeting, showcasing the production of anti-SARS-CoV-2 antibodies in mice and advancements in manufacturing efficiency. The first quarter results revealed a cash position of $451.1 million and R&D expenses of $18.8 million. However, the company recorded a net loss of $25.6 million, widening from the previous year. Generation Bio aims to leverage these developments to address a range of diseases and drive future growth.
Generation Bio Co (Nasdaq: GBIO) has announced three digital presentations for the American Society of Gene & Cell Therapy (ASGCT) 2021 Virtual Annual Meeting from May 11-14. These presentations will showcase data on their innovative non-viral gene therapy platform, focusing on antibody gene therapy, hemophilia A programs, and ceDNA construct engineering. Chief Scientific Officer Matthew Stanton noted that the hemophilia A program is progressing well, with additional data expected by mid-year. Registered attendees can access the presentations beginning May 11.
Generation Bio Co. (Nasdaq: GBIO), a genetic medicines company, announced that its CEO, Geoff McDonough, will join a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 3:00 p.m. ET. A live webcast will be accessible via the company's investor website, with a replay available for 30 days post-event. Generation Bio focuses on non-viral gene therapies, utilizing innovative technology such as closed-ended DNA (ceDNA) and cell-targeted lipid nanoparticles (ctLNP) to provide solutions for rare diseases.
Generation Bio Co. (Nasdaq: GBIO) reported strong financials for 2020, ending the year with a cash balance of $262.3 million, bolstered by $211.3 million raised in early 2021. Notably, the company has a successful follow-on offering, raising $225.4 million in January 2021. The company also announced promising preclinical data for its hemophilia A program, showing potential for significant factor VIII expression. Despite a net loss of $80.5 million in 2020, the company remains focused on advancing its pipeline through planned milestones in 2021.
Generation Bio (Nasdaq: GBIO) announced the appointment of Ron Cooper to its Board of Directors, effective March 1, 2021. Cooper, a seasoned biopharmaceutical executive, has led Albireo Pharma since June 2015 and has a strong background with Bristol Myers Squibb. His experience in commercializing products and working in rare diseases is expected to bolster Generation Bio during its critical growth phase. The company focuses on innovative non-viral gene therapies for rare diseases, aiming to enhance treatment durability and scalability.
Generation Bio Co. (Nasdaq: GBIO) closed its public offering of 9,200,000 shares at $24.50 each, generating approximately $225.4 million gross proceeds. This includes 1,200,000 shares from underwriters' option to purchase more. Joint bookrunning managers for the offering were J.P. Morgan, Jefferies, and Cowen. The funds raised will support the company's innovative gene therapy efforts aimed at treating both rare and prevalent diseases through its proprietary non-viral delivery platform.
Generation Bio Co. (Nasdaq: GBIO) has priced a public offering of 8,000,000 shares of its common stock at $24.50 per share. With a 30-day option for underwriters to purchase an additional 1,200,000 shares, the gross proceeds are estimated at approximately $196.0 million, pending closing on January 11, 2021. J.P. Morgan, Jefferies, and Cowen are leading the offering, with a focus on advancing their innovative gene therapy technology aimed at treating rare and prevalent diseases.
Generation Bio Co. (Nasdaq: GBIO) announced it will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021. CEO Geoff McDonough will share insights on the company’s progress and upcoming milestones. Recently, Generation Bio achieved a key scientific milestone by demonstrating human factor VIII expression in hemophilia A mice, reaching 23% of normal levels. They also confirmed the successful translation of their liver-targeted delivery system into non-human primates, supporting further studies for hemophilia A treatments.
Generation Bio (NASDAQ: GBIO) has achieved significant progress in its non-viral gene therapy platform, particularly for hemophilia A treatments. Their recent study demonstrated a mean human factor VIII expression of 23% of normal in hemophilia A mice after a single dose of closed-ended DNA (ceDNA) delivered via cell-targeted lipid nanoparticles (ctLNPs). Notably, the therapy was well tolerated across all tested doses in both mice and non-human primates. Generation Bio is on track to select a final candidate for clinical development and begin IND-enabling studies this year.
Generation Bio Co. (Nasdaq: GBIO) announced progress in its non-viral gene therapy programs and third-quarter financial results. The company is on track to advance lead programs into IND-enabling preclinical development in 2021, backed by a strong cash position of $280.4 million as of September 30, 2020. R&D expenses rose to $15.3 million, while G&A expenses increased to $5.7 million, resulting in a net loss of $20.8 million. Key leadership appointments were also announced, including Tracy Zimmermann as Chief Development Officer and Doug Kerr as Chief Medical Officer, to enhance R&D capabilities.